NIPT screening & Nuchal Translucency - Complimentary rather than alternatives

Posted by Professor Mike O’Connor AM on 2 May 2018
The advent of the Non Invasive Prenatal Test has been a major advance for the detection of Trisomy 21 (Down s.), Trisomy 18 (Edwards s.) & Trisomy 13 (Patau s.) and reduces the need for invasive tests which have up to a 3% risk of miscarriage. There has been a subsequent tendency to abandon the previous nuchal translucency ultrasound and biochemical test because of the increased accuracy of detection of the trisomies with the NIPT test which can detect 99% of Down syndrome fetuses ...
Posted in: Obstetrcis Ultrasound Miscarriage  

Women's Health Screening _Quo Vadis?

Posted by Professor Mike O’Connor AM on 15 February 2018
The recent Federal Government decision to rebate cervical cancer screening only every 5 years and to only rebate for screening after the age of 24 years and under the age of 74 years raises the question as to whether other aspects of women's health could be also screened far less frequently. That could be an unintended negative consequence of the recent Government funding decision.  The chance of an Australian woman being diagnosed with a gynaecological cancer by age 85 is 1:5...
Posted in: Other  

Inaugural South Pacific Medical Student's Medical Camp

Posted by Professor Mike O’Connor AM on 1 January 2018
I recently returned from the inaugural South Pacific Medical Student's Medical Camp in Malolo Island, Fiji. 120 medical students from Fiji, Tonga, Samoa, Papua New Guinea as well as New Zealand and Australia spent a week on a tribal area in the school grounds courtesy of the local chief. The dais was a single structure decorated with palm leaves and the audience sat under a similar structure 25 metres away. There were some fascinating lectures from plant biologists, climatologists,...
Posted in: Other  

Ovarian Tumour Markers-false positives

Posted by Professor Mike O’Connor AM on 21 November 2016
The use of ovarian tumour mark-ers, like those for other tumours, are used both to suggest the presence of a tumour as well as monitor its remission after de-finitive treatment. The problem is the lack of specificity which means that many non malignant processes can be associated with elevated values or that the malignancy is non-gynaecological. CA125. Cancer antigen 125 (CA 125) is used the most extensively. Approximately 60% of malignant ovarian tumours are associated with an elevate...
Posted in: Ovaries  

The importance of saying no

Posted by Professor Mike O’Connor AM on 11 August 2016
(as featured in O&G Magazine) Qui Tacet Consentire Videtur She who is silent appears to consent. We all appreciate consultations where the patient is accepting of the advice offered and has but few questions. However, silence during the process of consent may be no longer as 'golden' as it once was. It may be a dangerous prelude to a medicolegal action which was, in retrospect, totally preventable. Read more... ...
Posted in: Medicolegal  

Our Accreditation

Call Us On(02) 9588 2466